At #ESMO25, we’re proud to continue our legacy of advancing cancer care with 25 posters, 2 mini oral presentations, and 4 proffered paper presentations. Visit the Pfizer Oncology Medical booth #2044 and explore the full congress program here: pfi.sr/NEV

Join Pfizer Oncology Medical at #ESMO25! Visit our poster presentations on #GynecologicalCancer and #UrothelialCancer to learn how we're advancing cancer research. Explore the congress program here for more details: pfi.sr/NzD

Don’t miss Pfizer Oncology Medical’s poster presentations at #ESMO25 and stay at the forefront of #NSCLC research! Learn more in the congress program here: pfi.sr/NzD

Attend this proffered paper session at #ESMO25 to explore results from a phase 3 study of perioperative nectin-4-directed ADC + PD-1 inhibitor in patients with muscle-invasive #BladderCancer ineligible for platinum-based chemotherapy: pfi.sr/Nvt

Explore findings from an updated overall survival analysis of phase 2 study patients with BRAF V600E-mutant metastatic #NSCLC receiving a BRAF V600E kinase inhibitor + MEK1/2 inhibitor at our mini oral presentation during #ESMO25: pfi.sr/Nv9

Visit Pfizer Oncology Medical at our #ESMO25 proffered paper session to explore overall survival in patients with biochemically recurrent #ProstateCancer treated with an androgen receptor pathway inhibitor pfi.sr/Nvy

Mark your schedule for these #ESMO25 poster presentations and explore the latest research from Pfizer Oncology Medical. You can find the full congress program here: pfi.sr/Nzz

At #ESMO25, attend Pfizer Oncology Medical's proffered paper session for valuable insights into a ctDNA analysis of BRAF V600E dynamics in phase 3 study patients treated for BRAF V600E-mutant metastatic #ColorectalCancer: pfi.sr/Nvj

A new NEJM publication examines androgen receptor inhibition in biochemically recurrent #ProstateCancer. Learn how hormonal modulation may inform clinical decision-making. Read more: pfi.sr/N82

Explore findings from this phase 3 trial at our mini oral presentation during #ESMO25 to learn more about the impact of adding a CDK4/6 inhibitor to HER2 and endocrine therapy on HRQoL after induction in HR+/HER2+ metastatic #BreastCancer: pfi.sr/NvC

Can AI improve how we conduct systematic reviews in oncology? A new publication shows how machine learning can enhance text screening for cardiotoxicity studies—boosting speed and sensitivity. Read more: pfi.sr/NLb

See a comparison of patient-reported peripheral neuropathy in triple-class refractory #MultipleMyeloma in clinical trial patients receiving a BCMA-CD3 BsAb versus patients in a real-world study given physician’s choice of therapy: pfi.sr/xkq

In this podcast, two oncologists and a nurse practitioner discuss strategies for managing treatment and adverse events for a nectin-4 ADC + PD-1 inhibitor in patients with locally advanced/metastatic #UrothelialCancer. Listen now: pfi.sr/Nb7

Discover how reduced dosing frequency of a BCMA-CD3 bispecific antibody affects patient-reported outcomes in patients with relapsed/refractory #MultipleMyeloma in this phase 2 study: pfi.sr/NVw

Learn about dosing, pharmacokinetics, and potential drug interactions with an ARPI for the treatment of advanced #ProstateCancer in this podcast featuring hypothetical patient cases with real-world clinical implications: pfi.sr/xkp

Listen to this podcast to learn about treatments for metastatic/nonmetastatic hormone-sensitive #ProstateCancer, focusing on therapies that target the androgen-sensitive pathway. Explore patient-specific treatment selection and barriers to treatment: pfi.sr/x3b

A new publication from the Phase 2 PHAROS study highlights updated follow-up data on overall survival in adult pts with BRAF V600E-mutant metastatic non-small cell lung cancer. Read more: pfi.sr/xZs

Learn more about the long-term safety of an ALK tyrosine kinase inhibitor, including adverse event management, in patients with ALK+ advanced/metastatic non-small cell #LungCancer in the 5-year follow-up of this phase 3 study: pfi.sr/xw9

Discover how a new MAIC study compares androgen receptor pathway inhibitors in mHSPC, offering insights into treatment strategies and clinical outcomes. Read the full publication in Future Oncology: pfi.sr/NVB

As #ESMO25 ends, we’d like to thank everyone who visited Pfizer Oncology Medical! We’re inspired by the shared commitment to advancing oncology care and proud to have shared our latest research. If you missed us, explore our congress resources online: pfi.sr/xGL